company background image
IPSE.Y logo

Ipsen OTCPK:IPSE.Y Stock Report

Last Price

US$30.67

Market Cap

US$10.3b

7D

0.7%

1Y

8.5%

Updated

21 Jan, 2025

Data

Company Financials +

IPSE.Y Stock Overview

Operates as a biopharmaceutical company worldwide. More details

IPSE.Y fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends4/6

My Notes

Capture your thoughts, links and company narrative

Ipsen S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ipsen
Historical stock prices
Current Share Price€30.67
52 Week High€34.06
52 Week Low€27.00
Beta0.62
1 Month Change12.43%
3 Month Change-1.32%
1 Year Change8.49%
3 Year Change27.24%
5 Year Change71.05%
Change since IPO69.66%

Recent News & Updates

Recent updates

Shareholder Returns

IPSE.YUS PharmaceuticalsUS Market
7D0.7%0.4%3.8%
1Y8.5%1.4%24.4%

Return vs Industry: IPSE.Y exceeded the US Pharmaceuticals industry which returned 0.2% over the past year.

Return vs Market: IPSE.Y underperformed the US Market which returned 23.7% over the past year.

Price Volatility

Is IPSE.Y's price volatile compared to industry and market?
IPSE.Y volatility
IPSE.Y Average Weekly Movement4.9%
Pharmaceuticals Industry Average Movement10.7%
Market Average Movement6.5%
10% most volatile stocks in US Market18.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: IPSE.Y has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IPSE.Y's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19295,325David Loewwww.ipsen.com

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

Ipsen S.A. Fundamentals Summary

How do Ipsen's earnings and revenue compare to its market cap?
IPSE.Y fundamental statistics
Market capUS$10.27b
Earnings (TTM)US$691.56m
Revenue (TTM)US$3.58b

14.8x

P/E Ratio

2.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IPSE.Y income statement (TTM)
Revenue€3.44b
Cost of Revenue€618.00m
Gross Profit€2.82b
Other Expenses€2.15b
Earnings€663.90m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)8.08
Gross Margin82.01%
Net Profit Margin19.33%
Debt/Equity Ratio9.6%

How did IPSE.Y perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

15%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 09:48
End of Day Share Price 2025/01/21 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ipsen S.A. is covered by 36 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Charles Pitman-KingBarclays
Hae Won NaBerenberg